CL2023002189A1 - Materiales y métodos para el seguimiento del cáncer mediante la administración de un anticuerpo anti-mcl1 - Google Patents

Materiales y métodos para el seguimiento del cáncer mediante la administración de un anticuerpo anti-mcl1

Info

Publication number
CL2023002189A1
CL2023002189A1 CL2023002189A CL2023002189A CL2023002189A1 CL 2023002189 A1 CL2023002189 A1 CL 2023002189A1 CL 2023002189 A CL2023002189 A CL 2023002189A CL 2023002189 A CL2023002189 A CL 2023002189A CL 2023002189 A1 CL2023002189 A1 CL 2023002189A1
Authority
CL
Chile
Prior art keywords
methods
administering
materials
mcl
cancer monitoring
Prior art date
Application number
CL2023002189A
Other languages
English (en)
Inventor
Kielczewska Agnieszka
Chan Brian
C Boyle Michael
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2023002189A1 publication Critical patent/CL2023002189A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

La divulgación proporciona anticuerpos anti-Mcl-1 de cualquier forma, y fragmentos de los mismos, que se unen al antígeno con una unión inesperadamente alta a Mcl-1, proporcionando herramientas útiles en métodos de seguimiento de células cancerosas que expresan Mcl-1 y métodos de tratamiento de cánceres, particularmente cánceres sanguíneos, que comprenden dichas células cancerosas.
CL2023002189A 2021-01-29 2023-07-25 Materiales y métodos para el seguimiento del cáncer mediante la administración de un anticuerpo anti-mcl1 CL2023002189A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163143682P 2021-01-29 2021-01-29

Publications (1)

Publication Number Publication Date
CL2023002189A1 true CL2023002189A1 (es) 2024-03-01

Family

ID=82654972

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023002189A CL2023002189A1 (es) 2021-01-29 2023-07-25 Materiales y métodos para el seguimiento del cáncer mediante la administración de un anticuerpo anti-mcl1

Country Status (14)

Country Link
US (1) US20240117069A1 (es)
EP (1) EP4284826A1 (es)
JP (1) JP2024508222A (es)
KR (1) KR20230135087A (es)
CN (1) CN116806156A (es)
AU (1) AU2022214936A1 (es)
CA (1) CA3203780A1 (es)
CL (1) CL2023002189A1 (es)
CO (1) CO2023009810A2 (es)
CR (1) CR20230388A (es)
IL (1) IL303844A (es)
MX (1) MX2023008971A (es)
PE (1) PE20231731A1 (es)
WO (1) WO2022165240A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020086321A1 (en) * 1993-02-02 2002-07-04 Craig Ruth W. Myeloid cell leukemia associated gene MCL-1
US20100040606A1 (en) * 2006-03-06 2010-02-18 Symphogen A/S Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections
ES2610607T3 (es) * 2007-05-21 2017-04-28 Alderbio Holdings Llc Anticuerpos contra IL-6 y usos de los mismos
CA2932547C (en) * 2014-01-06 2023-05-23 F. Hoffmann-La Roche Ag Monovalent blood brain barrier shuttle modules
WO2019160007A1 (ja) * 2018-02-14 2019-08-22 中外製薬株式会社 抗原結合分子および組合せ
JP7205691B2 (ja) * 2019-01-23 2023-01-17 ウシオ電機株式会社 抗イヌプロカルシトニン抗体及びこれを用いた検査用キット

Also Published As

Publication number Publication date
CR20230388A (es) 2023-10-05
JP2024508222A (ja) 2024-02-26
CA3203780A1 (en) 2022-08-04
MX2023008971A (es) 2023-08-15
CN116806156A (zh) 2023-09-26
WO2022165240A1 (en) 2022-08-04
AU2022214936A1 (en) 2023-06-29
CO2023009810A2 (es) 2023-08-09
PE20231731A1 (es) 2023-10-26
EP4284826A1 (en) 2023-12-06
KR20230135087A (ko) 2023-09-22
US20240117069A1 (en) 2024-04-11
AU2022214936A9 (en) 2023-08-17
IL303844A (en) 2023-08-01

Similar Documents

Publication Publication Date Title
CL2018002490A1 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123. (divisional solicitud 201701866)
AR114002A1 (es) Anticuerpos a lilrb2
CL2019001198A1 (es) Anticuerpo bioespecífico contra bcma y cd3 y un fármaco inmunológico para uso combinado en el tratamiento de mieloma múltiple.
CL2020001974A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos. (divisional solicitud 201903093)
UY36859A (es) Anticuerpos anti-bcma, moléculas de unión a antígenos biespecíficas que se unen a bcma y cd3, y usos de estas
CL2018002763A1 (es) Moléculas de unión a bcma y métodos de uso de las mismas.
CL2019001926A1 (es) Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017).
UY38236A (es) COMBINACIONES FARMACÉUTICAS QUE CONTIENEN EL ANTICUERPO ANTI-CD38, ASOCIADO CON LOS ANTICUERPOS BIOESPECÍFICOS BCMAxCD3 O GPRC5DxCD3 O CD19xCD3
AR068818A1 (es) Terapia de combinacion con anticuerpos anti-cd20, de tipo i y de tipo ii para el tratamiento del cancer , uso, kit
NI201900103A (es) Anticuerpos anti-ilt4 y fragmentos de unión a antígeno
CY1119799T1 (el) Συνδυασμος αντισωματων anti-kir και αντισωματων anti-pd-1 για αγωγη καρκινου
CO2017005650A2 (es) Anticuerpos anti-interleucina-33
AR113342A1 (es) Anticuerpos específicos cd47 / pd-l1
PE20181399A1 (es) Anticuerpos y fragmentos de anticuerpo para la conjugacion sitio-especifica
CO2018011195A2 (es) Composiciones que comprenden una coformulación de anticuerpos anti-pd-l1 y anti-ctla-4
CR20190079A (es) Anticuerpos anti-tim-3
PE20181349A1 (es) Anticuerpos biespecificos con tetravalencia para un receptor de fnt coestimulador
CO2020000214A2 (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos
UY37761A (es) Anticuerpos que se unen específicamente a pd-1 y métodos de uso
BR112018015480A2 (pt) proteínas de ligação ao antígeno que se ligam a pd-l1
AR113429A1 (es) Terapia combinada de agonistas de icos dirigidos a tumores con moléculas biespecíficas de linfocitos t
CL2020002600A1 (es) Anticuerpo anti-muerte programada-ligando 1 y su uso
PE20181050A1 (es) Anticuerpos contra csf-1r humano para su uso en la induccion de linfocitosis en linfomas o leucemias
CL2021001813A1 (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r.
DOP2023000158A (es) Anticuerpo triespecífico dirigido a bcma, gprc5d, y cd3